Free Trial

Collegium Pharmaceutical (COLL) News Today

Collegium Pharmaceutical logo
$29.58 -0.69 (-2.28%)
(As of 11/15/2024 ET)
Collegium to Participate in Upcoming Investor Conferences
Collegium Pharmaceutical, Inc. stock logo
Meritage Portfolio Management Purchases Shares of 19,776 Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Meritage Portfolio Management bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 19,776 shares of the specialty pharmaceutical company's stock, valued
Collegium Pharmaceutical, Inc. stock logo
Principal Financial Group Inc. Buys 64,958 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Principal Financial Group Inc. increased its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 3.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,745,818 shares of the specialty pharmaceutical com
Collegium Pharmaceutical, Inc. stock logo
Robeco Institutional Asset Management B.V. Has $4.44 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Robeco Institutional Asset Management B.V. boosted its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 265.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 114,965 shares of the specialty pha
Collegium Pharmaceutical Reports Strong Q3 2024 Results
Collegium Pharmaceutical appoints Vikram Karnani as CEO
Piper Sandler Remains a Hold on Pacira Pharmaceuticals (PCRX)
Collegium Pharmaceutical Taps Vikram Karnani as CEO
Collegium Appoints Vikram Karnani as Chief Executive Officer
A Preview Of Collegium Pharmaceutical's Earnings
Collegium Pharmaceutical, Inc. stock logo
Emerald Advisers LLC Boosts Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Emerald Advisers LLC boosted its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 27.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 827,302 shares of the specialt
Collegium Pharmaceutical, Inc. stock logo
Collegium Pharmaceutical (COLL) to Release Quarterly Earnings on Thursday
Collegium Pharmaceutical (NASDAQ:COLL) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=639719)
Collegium Pharmaceutical (COLL) Receives a Buy from Truist Financial
Collegium Pharmaceutical, Inc. stock logo
Allspring Global Investments Holdings LLC Purchases 36,331 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Allspring Global Investments Holdings LLC grew its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 83.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 79,822 shares of the specialty pha
Collegium Pharmaceutical, Inc. stock logo
Assenagon Asset Management S.A. Sells 188,423 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Assenagon Asset Management S.A. lessened its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 52.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 173,714 shares of the specialty pharmaceutical compan
Collegium Pharmaceutical, Inc. stock logo
StockNews.com Downgrades Collegium Pharmaceutical (NASDAQ:COLL) to Buy
StockNews.com cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Wednesday.
Collegium Pharmaceutical, Inc. stock logo
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Inspire Investing LLC
Inspire Investing LLC lessened its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 64.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,813 shares of the specialty pharmaceutical company's stock
Collegium Pharmaceutical, Inc. stock logo
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Short Interest Down 6.5% in September
Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) was the recipient of a large decline in short interest in the month of September. As of September 30th, there was short interest totalling 5,940,000 shares, a decline of 6.5% from the September 15th total of 6,350,000 shares. Currently, 19.0% of the company's shares are short sold. Based on an average daily volume of 432,200 shares, the short-interest ratio is presently 13.7 days.
Collegium Pharmaceutical, Inc. stock logo
Sanctuary Advisors LLC Makes New Investment in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Sanctuary Advisors LLC bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 16,245 shares of the specialty pharmaceutical
Collegium Pharmaceutical, Inc. stock logo
Collegium Pharmaceutical (NASDAQ:COLL) Rating Increased to Strong-Buy at StockNews.com
StockNews.com upgraded Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Tuesday.
Collegium Pharmaceutical (COLL) Receives a Hold from Piper Sandler
Collegium Pharmaceutical, Inc. stock logo
Collegium Pharmaceutical (NASDAQ:COLL) Given "Neutral" Rating at Piper Sandler
Piper Sandler reaffirmed a "neutral" rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday.
Collegium Pharmaceutical, Inc. stock logo
Millennium Management LLC Buys 110,499 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Millennium Management LLC boosted its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 57.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 303,870 shares
Collegium Pharmaceutical, Inc. stock logo
70,964 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Acquired by Marshall Wace LLP
Marshall Wace LLP bought a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 70,964 shares of the specialty pharmaceutical company's stock, valued at approximately $2,285
Collegium Pharmaceutical, Inc. stock logo
Squarepoint Ops LLC Has $3.55 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Squarepoint Ops LLC grew its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 194.5% in the second quarter, according to its most recent filing with the SEC. The fund owned 110,338 shares of the specialty pharmaceutical company's stock after acquiring an additional 72,874 s
Collegium Pharmaceutical, Inc. stock logo
Maverick Capital Ltd. Acquires 30,723 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Maverick Capital Ltd. boosted its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 346.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 39,596 shares of the specialty pharmaceutical company's stock
Collegium Pharmaceutical, Inc. stock logo
Mutual of America Capital Management LLC Cuts Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Mutual of America Capital Management LLC reduced its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 18.2% during the second quarter, according to its most recent filing with the SEC. The fund owned 75,928 shares of the specialty pharmaceutical company's stock after selling 1
Collegium Pharmaceutical, Inc. stock logo
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Rubric Capital Management LP
Rubric Capital Management LP raised its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 27.2% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,333,500 shares of the specialty pharmace
Collegium Pharmaceutical, Inc. stock logo
Renaissance Technologies LLC Increases Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Renaissance Technologies LLC grew its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 8.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,531,498 shares of the specialty pharmaceutical company's stock
Collegium Pharmaceutical, Inc. stock logo
Bokf Na Purchases New Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Bokf Na acquired a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 15,208 shares of the specialty pharmaceutical co
Collegium Pharmaceutical, Inc. stock logo
Victory Capital Management Inc. Sells 31,149 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Victory Capital Management Inc. trimmed its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 5.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 494,814 shares of the sp
Collegium Pharmaceutical, Inc. stock logo
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Rating of "Moderate Buy" from Brokerages
Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) has received a consensus rating of "Moderate Buy" from the five analysts that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and three have issued a buy r
Collegium Pharmaceutical, Inc. stock logo
Q3 2024 Earnings Estimate for Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Issued By HC Wainwright
Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) - Equities research analysts at HC Wainwright lifted their Q3 2024 earnings estimates for Collegium Pharmaceutical in a research note issued on Wednesday, September 4th. HC Wainwright analyst O. Livnat now expects that the specialty pharm
Collegium Pharmaceutical, Inc. stock logo
Emerald Advisers LLC Trims Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)
Emerald Advisers LLC trimmed its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 2.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 650,173 shares of
Get Collegium Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.

There is a little known company that is changing warfare (Ad)

With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.

Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t

COLL Media Mentions By Week

COLL Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

COLL
News Sentiment

0.87

0.56

Average
Medical
News Sentiment

COLL News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

COLL Articles
This Week

6

4

COLL Articles
Average Week

Get Collegium Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:COLL) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners